LadRx

LadRx Equity

The The Equity of LadRx (LADX) as of Oct 19, 2026 is -1.42 M USD. In the previous year, The Equity was 107,354.00 USD — a change of -1,422.19% (lower).

Equity

-1.42 MUSD

YoY

-1,422.19%

Last updated:

In 2024, LadRx's equity was -1.42 M USD, a -1,422.19% increase from the 107,354.00 USD equity in the previous year.

The LadRx Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
20.36 M USD
Jan 1, 2019
15.20 M USD
Jan 1, 2020
8.87 M USD
Jan 1, 2021
4.78 M USD
Jan 1, 2022
25,720.00 USD
Jan 1, 2023
107,354.00 USD
Jan 1, 2024
-1.42 M USD
The LadRx Equity history
YEAREquityYoY
-1.42 MUSD-1,422.19%
107,354.00USD+317.40%
25,720.00USD-99.46%
4.78 MUSD-46.16%
8.87 MUSD-41.66%
15.20 MUSD-25.33%
20.36 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

LadRx Stock analysis

What does LadRx do? LadRx Corp, with ticker LADX and ISIN US2328287071, is a biotechnology company headquartered in Los Angeles, United States. The company has 2 employees and went public on November 10, 1986. Its website is http://www.cytrx.com/. LadRx Corp operates within the Health Care sector, specifically in the Biotechnology industry. The company's activities include the discovery, research, and clinical development of anti-cancer drug candidates. It focuses on aldoxorubicin, a modified version of doxorubicin, for clinical development. The company is involved in Phase III trials for aldoxorubicin as a treatment for soft tissue sarcoma in patients whose tumors have progressed after chemotherapy. Additionally, LadRx Corp is conducting Phase IIb trials for aldoxorubicin in small cell lung cancer, Phase II trials for HIV-related Kaposi's sarcoma, and Phase II trials for late-stage glioblastoma. The company also has Phase Ib trials combining aldoxorubicin with ifosfamide for soft tissue sarcoma and with gemcitabine for metastatic solid tumors. LadRx Corp is developing DK049, an anti-cancer drug conjugate utilizing its LADR technology, in pre-clinical stages. The company's website and public filings provide further details on its operations and clinical trials. LadRx is one of the most popular companies on Eulerpool.

Equity Details

Analyzing LadRx's Equity

LadRx's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding LadRx's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating LadRx's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

LadRx's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in LadRx’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about LadRx stock

The Equity of LadRx is -1.42 M USD in 2024.

The Equity of LadRx changed from 107,354.00 USD to -1.42 M USD, representing a -1,422.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity LadRx since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's LadRx historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — LadRx

All Key Metrics — LadRx